L'Oréal S.A. (OR.PA)
| Previous Close | 441.40 |
| Open | 439.55 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 437.80 - 440.55 |
| 52 Week Range | 330.00 - 442.60 |
| Volume | |
| Avg. Volume | 330,444 |
| Market Cap | 234.611B |
| Beta (5Y Monthly) | 0.71 |
| PE Ratio (TTM) | 40.40 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 6.00 (1.36%) |
| Ex-Dividend Date | Apr 26, 2023 |
| 1y Target Est | N/A |
- Reuters
Hair relaxer claims against L'Oreal, Revlon can proceed -U.S. judge
A federal judge on Monday allowed the majority of claims to move forward in sprawling litigation that claims chemical hair relaxer products made by L'Oreal USA, Revlon and others cause cancer and other injuries. Illinois-based U.S. District Judge Mary Rowland denied most of the companies’ arguments in their motion to dismiss the complaint in the multidistrict litigation over the products. Of the 15 counts in the complaint, Rowland dismissed three entirely and a portion of a fourth, finding the plaintiffs had not done enough to bolster their claims that the companies committed fraud.
- Reuters
INSIGHT-Thousands of Black women claim hair relaxers gave them cancer
Sheila Bush, a cosmetologist, was lounging in the recliner at her St. Louis-area home last winter when an advertisement from a law firm flashed up on her television screen, urging viewers to call a toll-free number if they or a loved one had used hair relaxers and been diagnosed with uterine cancer. After seeing the ad three times, Bush, who said she had used hair relaxers every six weeks for most of her life and was diagnosed with uterine cancer about a decade ago, decided to pick up the phone. The ads Bush saw, on television as well as on her social media feeds, were part of a nationwide effort by law firms to sign up Black women to file lawsuits alleging at least a dozen cosmetic companies, including L'Oreal and Revlon, sold hair relaxers containing chemicals that increased the risk of developing uterine cancer – and failed to warn customers.
- Reuters
Brazil's Natura in exclusive talks with Aurelius for The Body Shop sale
SAO PAULO (Reuters) -Brazilian cosmetic maker Natura & Co on Monday said it has agreed to enter into exclusive talks with private investor Aurelius Group for a potential sale of its subsidiary The Body Shop (TBS), lifting its Sao Paulo-traded shares. The move comes after Natura announced in August that its board of directors had authorized it to search for "strategic alternatives" for TBS, including a potential sale of the business, six years after buying it from L'Oreal. Shares of the Brazilian firm rose more than 2% on the news, which also follows a deal earlier this year to sell its luxury brand Aesop to L'Oreal at an enterprise value of $2.53 billion as part of a broader organizational shakeup.
